One-Year Follow-Up Shows 71.4% Progression-Free Survival in 14 Prostate Cancer Patients Treated with ProscaVax in Phase 1 Clinical Trial

BATON ROUGE, La., Dec. 21, 2017 -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology, targeted cancer therapies and commercialization of a portfolio of products internationally, is pleased to provide one-year follow-up results from the Company’s Phase 1 clinical trial of ProscaVax for prostate cancer.

In the trial, hormone-naïve and hormone-independent recurrent prostate cancer patients with increasing prostate specific antigen (PSA) were treated with six intradermal injections of ProscaVax. ProscaVax is OncBioMune's novel immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated PSA with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF). 

The latest data shows:

• Progression-Free Survival 71.4%:  10 of 14 patients (71.4%), who have been followed for one year after initiation of ProscaVax therapy, continue to have stable disease
• Overall Survival 100%:  None of the 14 evaluable patients have died at one-year follow-up
• As previously disclosed, four patients had disease progression within 19 weeks (3 PSA progression and 1 radiological progression).  No further progression has been noted from week 19 to one year
• Data continues to confirm there were no drug-related serious adverse events or dose-limiting toxicities resulting from ProscaVax therapy
• Six of the 20 patients enrolled in the trial have not yet been followed for one year, evaluations to follow

“I continue to be impressed with the clinical results on ProscaVax. These results support the benefit of this first-in-class immunotherapy and offers hope to cancer patients in great need,” commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. “These are men who have tried conventional treatments only to have their cancer return and where ProscaVax now seems to be delivering a therapeutic benefit. While Progression-Free Survival and Overall Survival are benchmarks of later-stage studies and not the primary endpoints in our Phase 1 clinical trial, it is hard to overlook the finding that patients with progressing disease now have stable disease following ProscaVax therapy. We need to conduct a larger-scale clinical trial and build more complete data sets to confirm these results, but all signs at this time are pointing to ProscaVax having a meaningful effect by increasing PSA doubling time and inhibiting tumor growth in prostate cancer. It is reason to be optimistic about the next stage of research.”

Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, including a proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. OncBioMune is also involved in drug development and commercialization internationally through our wholly-owned subsidiary, OncBioMune México, S.A. De C.V. Our lead pipeline product, ProscaVax™, is scheduled to commence two, separate mid-stage clinical trials: a Phase 2 for early-stage prostate cancer at a major Northeast U.S. university cancer research hospital and a Phase 2/3 study in Mexico for late-stage prostate cancer patients. OncBioMune has a portfolio of targeted and licensed therapies, some of which are biosimilars and generics to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals' actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.  

Contact:

OncBioMune Pharmaceuticals, Inc.
Andrew Kucharchuk
President and Chief Financial Officer
[email protected]